News
Trial results, approvals, pricing changes, safety findings and market moves across peptides and GLP-1 medications — each traced to a primary source, each dated. For enforcement actions specifically, see the regulatory tracker.
- Trial results
- Approvals
- Pricing changes
- Safety findings
-
Survodutide cut weight by up to 9.8% in people with type 2 diabetes
Read more: Survodutide cut weight by up to 9.8% in people with type 2 diabetesSurvodutide, an experimental once-weekly injection from Boehringer Ingelheim that acts on both the GLP-1 and glucagon receptors, reduced body weight by 8.2% to 9.8% over 76 weeks in adults with obesity and type 2 diabetes, against 3.9% on placebo, in a phase 3 trial published in the New England Journal of Medicine on 1 October.…
-
Medicaid coverage of Wegovy and Zepbound added fewer prescriptions than it appeared
Read more: Medicaid coverage of Wegovy and Zepbound added fewer prescriptions than it appearedWhen a state Medicaid programme starts paying for GLP-1 drugs labeled for obesity, the bill for those drugs goes up. A study in JAMA Health Forum suggests the net increase is smaller than that figure implies, because some of the new obesity-labeled prescriptions appear to replace diabetes-labeled versions of the same molecules, which every state…
-
34 trials in PMOS, formerly PCOS: diet and exercise moved insulin more than weight
Read more: 34 trials in PMOS, formerly PCOS: diet and exercise moved insulin more than weightA review of 34 randomised trials in PLoS Medicine has tested the standard first-line advice for polyendocrine metabolic ovarian syndrome (PMOS) — the condition long called polycystic ovary syndrome, or PCOS, recently renamed by an international consensus. Structured diet, exercise and behavioural programmes improved fasting insulin, and made regular menstrual cycles more likely, compared with…
-
Weight loss explained only part of semaglutide’s heart benefit in SELECT
Read more: Weight loss explained only part of semaglutide’s heart benefit in SELECTTwo analyses of the SELECT trial, published a day apart, reach the same uncomfortable conclusion from different directions. The first, in the European Heart Journal, tried to work out how much of semaglutide’s 20% reduction in heart attacks, strokes and cardiovascular deaths runs through weight loss and the other risk factors it improves, and could…
-
GLP-1 drugs linked to fewer deaths in adults with obesity and raised CRP
Read more: GLP-1 drugs linked to fewer deaths in adults with obesity and raised CRPAdults with obesity and a raised inflammatory marker who were prescribed a GLP-1 receptor agonist had fewer deaths, heart attacks and strokes over the following decade than closely matched adults given an older weight or diabetes drug, according to a study published on 21 September in the American Journal of Cardiology. The gap was driven…
-
Ultra-processed food tied to obesity and death in 8.8 million adults
Read more: Ultra-processed food tied to obesity and death in 8.8 million adultsUltra-processed foods are associated with higher rates of seven major health outcomes, obesity and overweight among them, according to a dose-response meta-analysis of 51 prospective cohort studies covering 8,819,894 adults, published on 22 September 2026 in Family Medicine and Community Health. People in the highest intake groups had a 23% higher rate of obesity or…
-
GLP-1 prescribing to people with no recorded indication rose 15-fold
Read more: GLP-1 prescribing to people with no recorded indication rose 15-foldPrescriptions for GLP-1 receptor agonists written to US adults with no documented reason for taking them rose roughly 15-fold between 2021 and 2025, according to an analysis of electronic health records published on 22 September in Obesity. Among 92.4 million adults whose records showed neither type 2 diabetes nor obesity with a qualifying comorbidity, about…
-
CagriSema beat tirzepatide on weight loss — at a tirzepatide dose of 5 mg
Read more: CagriSema beat tirzepatide on weight loss — at a tirzepatide dose of 5 mgNovo Nordisk announced this morning that CagriSema, its investigational combination of semaglutide and a second hormone, beat tirzepatide on weight loss in a head-to-head phase 3 trial in adults with type 2 diabetes: an estimated 12.4% against 9.1% at week 60. A second phase 3 trial put CagriSema at 21.0% weight loss against 2.0% on…
-
Waist measurements tracked visceral fat almost exactly in a 225-person tirzepatide trial
Read more: Waist measurements tracked visceral fat almost exactly in a 225-person tirzepatide trialA 225-person tirzepatide trial in Japan has reported its metabolic detail, and one finding is unusually practical: across the treatment groups, the change in waist measurement tracked the change in visceral fat — the fat wrapped around the internal organs, and the kind that carries the metabolic risk — with a correlation of 0.84. Visceral…
-
26 economic studies on weight-loss drugs, and what ‘cost-effective’ leaves out
Read more: 26 economic studies on weight-loss drugs, and what ‘cost-effective’ leaves outA systematic review has pulled together 26 economic evaluations of the approved weight-loss drugs, and the pattern it reports is worth knowing before anyone quotes “cost-effective” at you. Semaglutide came out ahead of liraglutide consistently enough that the authors call liraglutide generally not cost-effective. Tirzepatide bought the most health of any drug reviewed, and frequently…